WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global ...

NAMSA recently announced plans to acquire WuXi AppTec’s medical device testing operations in the U.S. As part of the ...

Over 3,000 people are employed across the network. Merck and WuXi Vaccines are now entering a formal handover process, expected to conclude in the first half of 2025. Once complete, the facility ...

Jan 6 (Reuters) - China's WuXi Biologics (2269.HK), opens new tab said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co (MRK.N), opens new tab for about $500 ...

Wuxi Biologics (WXXWY) plans to sell its Irish vaccine facility to Merck (MRK) for around $500M ahead of potential U.S. legislation that would limit business for Chinese biotech companies ...

At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling ...

China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to Merck for about $500 million. WuXi had previously said it was planning to sell some of its operations as the ...

WuXi 2269-1.25%decrease; red down pointing triangle Biologics agreed to sell an overseas vaccine facility to Merck MRK-1.32%decrease; red down pointing triangle & Co. for half a billion dollars ...

WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese company seeks to enhance its margins while continuing to navigate ...

A Merck KGaA brand logo stands in front of the company premises. WuXi Biologics, a Chinese biopharmaceuticals company, announced on 06 January the sale of its WuXi Vaccines facility in Ireland to ...

WuXi Biologics agreed to sell an overseas vaccine facility to Merck & Co. for half a billion dollars, a move that could strengthen the company's cash flow and margins as it navigates global ...